ArticleThe Journal of clinical investigation2024

MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer.

Yu-Wen Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.